BIOMAT Database Logo BIOMAT Database Logo

Plasminogen activators in ectopic and uterine endometrium. 1995

S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
University of Oxford, John Radcliffe Hospital, United Kingdom.

OBJECTIVE To investigate the expression of the plasminogen activator (PA)-plasmin system components in ectopic endometrium and in uterine endometrium from women with and without endometriosis. METHODS Plasminogen, PAs (urokinase and tissue plasminogen activator), and PA inhibitors (1 and 2) were detected by immunohistochemistry using a alkaline phosphatase staining method. RESULTS No differences in staining were found between uterine endometrium of women with endometriosis and women without endometriosis with any of the antibodies used. However, we did find differences between uterine and ectopic endometrium. Although the expression of the components of the PA-plasmin system reflected the cyclic changes in the hormonal levels in uterine endometrium, ectopic endometrium maintained a very high level of plasminogen and urokinase in every sample. We were unable to detect the presence of PA inhibitors in either uterine or ectopic endometrium. CONCLUSIONS There is no evidence that uterine endometrium from women with endometriosis is originally more able to implant than that of women without the disease because of an increase in their PA expression. The high levels of urokinase and plasminogen in ectopic endometrium may reflect a more invasive nature of the endometriotic implants in the peritoneal cavity.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D010958 Plasminogen Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent. Profibrinolysin,Glu-Plasminogen,Glutamic Acid 1-Plasminogen,Glutamyl Plasminogen,1-Plasminogen, Glutamic Acid,Glu Plasminogen,Glutamic Acid 1 Plasminogen,Plasminogen, Glutamyl
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004715 Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum. Endometrioma,Endometriomas,Endometrioses
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator

Related Publications

S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
[Plasminogen activators and plasminogen activator inhibitor type-1 in human endometrium].
October 1992, Sheng li xue bao : [Acta physiologica Sinica],
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Plasminogen activators in the endometrium. I. Methodological aspects.
January 1966, Acta obstetricia et gynecologica Scandinavica,
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Plasminogen activators in the human endometrium, cellular origin and hormonal regulation.
April 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Plasminogen activators and their inhibitors in normal, hyperplastic and carcinomatous human endometrium.
June 1986, Thrombosis research,
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Plasminogen activators in the endometrium of women using intrauterine contraceptive devices.
April 1976, British journal of obstetrics and gynaecology,
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Bone marrow-derived cell populations in uterine and ectopic endometrium.
September 1995, Human reproduction (Oxford, England),
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Ectopic endometrium in omentum. Uterine perforation by Lippes loop.
January 1975, Obstetrics and gynecology,
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Localization of matrix metalloproteinase-2 in uterine endometrium and ectopic implants.
January 1998, Gynecologic and obstetric investigation,
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
[Detection of tumor markers in uterine cancer (plasminogen activators, plasminogen activator inhibitors) using fibrin autography].
October 1992, Nihon Sanka Fujinka Gakkai zasshi,
S Fernández-Shaw, and J M Marshall, and B Hicks, and D H Barlow, and P M Starkey
Plasminogen activators in the endometrium. II. Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood loss.
January 1966, Acta obstetricia et gynecologica Scandinavica,
Copied contents to your clipboard!